Prevention of VTE: elective hip or knee replacement surgery: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.
Prevention of stroke: non-valvular atrial fibrillation: XALIQUIS is indicated to reduce the risk of stroke in patients with non-valvular atrial fibrillation with one or more risk factors, including patients unsuitable for warfarin/Vitamin K antagonist therapy (VKA).
Treatment of VTE: XALIQUIS is indicated for: Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); Prevention of recurrent DVT and PE.
Other Services
Country
Account